Arcturus Therapeutics Holdings Financial Statements (ARCT) |
||||||||||
Arcturus Therapeutics Holdingssmart-lab.ru | % | 2020 | 2021 | 2022 | 2023 | 2023 | LTM ? | |||
---|---|---|---|---|---|---|---|---|---|---|
Report date | 01.03.2021 | 01.03.2022 | 29.03.2023 | 31.12.2023 | 14.03.2024 | 08.05.2024 | ||||
Currency | USD | USD | USD | USD | USD | USD | ||||
Financial report URL | ||||||||||
Revenue, bln rub | ? | 9.54 | 12.4 | 205.8 | 169.9 | 157.7 | 138.2 | |||
Operating Income, bln rub | -71.5 | -202.9 | 12.2 | -75.1 | -4.15 | -76.0 | ||||
EBITDA, bln rub | ? | -71.8 | -200.4 | 11.7 | -75.1 | -1.20 | -70.2 | |||
Net profit, bln rub | ? | -71.4 | -206.9 | 9.35 | -26.6 | -29.7 | -60.2 | |||
OCF, bln rub | ? | -42.9 | -135.0 | 32.0 | -18.1 | -38.5 | ||||
CAPEX, bln rub | ? | 1.74 | 3.41 | 7.73 | 2.90 | 2.06 | ||||
FCF, bln rub | ? | -44.6 | -138.4 | 24.3 | -21.0 | -40.6 | ||||
Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
OPEX, bln rub | 81.1 | 215.2 | 193.6 | 245.0 | 158.9 | 213.3 | ||||
Cost of production, bln rub | 55.9 | 171.9 | 143.1 | 0.000 | 2.96 | 7.03 | ||||
R&D, bln rub | 57.8 | 173.8 | 147.8 | 192.1 | 109.0 | 168.1 | ||||
Interest expenses, bln rub | 0.361 | 2.67 | 0.420 | 0.000 | 0.767 | 0.024 | ||||
Assets, bln rub | 476.5 | 392.8 | 450.4 | 429.4 | 429.4 | 418.8 | ||||
Net Assets, bln rub | ? | 396.6 | 228.2 | 270.3 | 281.6 | 278.5 | 264.0 | |||
Debt, bln rub | 17.9 | 67.6 | 90.9 | 25.9 | 30.2 | 31.9 | ||||
Cash, bln rub | 462.9 | 370.5 | 391.9 | 347.0 | 347.0 | 288.4 | ||||
Net debt, bln rub | -445.0 | -302.9 | -301.0 | -321.1 | -316.8 | -256.5 | ||||
Ordinary share price, rub | 43.4 | 37.0 | 17.0 | 31.5 | 31.5 | 19.0 | ||||
Number of ordinary shares, mln | 20.3 | 26.3 | 26.4 | 26.6 | 26.6 | 26.9 | ||||
Market cap, bln rub | 881 | 974 | 449 | 840 | 840 | 510 | ||||
EV, bln rub | ? | 436 | 671 | 147 | 518 | 523 | 254 | |||
Book value, bln rub | 397 | 228 | 270 | 282 | 279 | 264 | ||||
EPS, rub | ? | -3.51 | -7.86 | 0.35 | -1.00 | -1.12 | -2.24 | |||
FCF/share, rub | -2.20 | -5.26 | 0.92 | 0.00 | -0.79 | -1.51 | ||||
BV/share, rub | 19.5 | 8.67 | 10.2 | 10.6 | 10.5 | 9.82 | ||||
EBITDA margin, % | ? | -752.6% | -1 621% | 5.67% | -44.2% | -0.76% | -50.8% | |||
Net margin, % | ? | -748.1% | -1 674% | 4.54% | -15.6% | -18.8% | -43.6% | |||
FCF yield, % | ? | -5.06% | -14.2% | 5.41% | 0.00% | -2.50% | -7.95% | |||
ROE, % | ? | -18.0% | -90.6% | 3.46% | -9.44% | -10.7% | -22.8% | |||
ROA, % | ? | -15.0% | -52.7% | 2.08% | -6.19% | -6.92% | -14.4% | |||
P/E | ? | -12.3 | -4.71 | 48.0 | -31.6 | -28.2 | -8.48 | |||
P/FCF | -19.7 | -7.04 | 18.5 | -40.0 | -12.6 | |||||
P/S | ? | 92.3 | 78.8 | 2.18 | 4.94 | 5.32 | 3.69 | |||
P/BV | ? | 2.22 | 4.27 | 1.66 | 2.98 | 3.01 | 1.93 | |||
EV/EBITDA | ? | -6.07 | -3.35 | 12.6 | -6.91 | -437.5 | -3.61 | |||
Debt/EBITDA | 6.20 | 1.51 | -25.8 | 4.28 | 265.1 | 3.65 | ||||
R&D/CAPEX, % | 3 321% | 5 102% | 1 912% | 3 758% | 8 167% | |||||
CAPEX/Revenue, % | 18.3% | 27.6% | 3.75% | 0.00% | 1.84% | 1.49% | ||||
Arcturus Therapeutics Holdings shareholders |